Patents by Inventor Christopher L. Carroll

Christopher L. Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PTPN11 inhibitors
    Patent number: 11945815
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: April 2, 2024
    Inventors: Philip Jones, Barbara Czako, Christopher L Carroll, Pijus Mandal, Jason Cross
  • ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES
    Publication number: 20230416261
    Abstract: Provided are ethanediamine-heterocycle compounds, and salts thereof, that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Application
    Filed: September 6, 2023
    Publication date: December 28, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy MCAFOOS, Christopher L. CARROLL, Zhijun KANG
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230008047
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: May 21, 2021
    Publication date: January 12, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • PTPN11 INHIBITORS
    Publication number: 20220041594
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 10, 2022
    Inventors: Philip JONES, Barbara CZAKO, Christopher L. CARROLL, Pijus MANDAL, Jason CROSS
  • PTPN11 inhibitors
    Patent number: 11104675
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 31, 2021
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Barbara Czako, Christopher L. Carroll, Pijus Mandal, Jason Cross
  • Imidazopiperazine inhibitors of transcription activating proteins
    Patent number: 11058688
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 13, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kang Le, Michael J. Soth, Philip Jones, Jason Bryant Cross, Christopher L. Carroll, Timothy Joseph McAfoos, Pijus Kumar Mandal
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 11001594
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 11, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • Imidazopiperazinone inhibitors of transcription activating proteins
    Patent number: 10899769
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: January 26, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kang Le, Michael J. Soth, Gang Liu, Philip Jones, Jason Bryant Cross, Timothy Joseph Mcafoos, Christopher L. Carroll, Richard T. Lewis
  • PTPN11 INHIBITORS
    Publication number: 20200048249
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: August 9, 2019
    Publication date: February 13, 2020
    Inventors: Philip JONES, Barbara CZAKO, Christopher L. CARROLL, Pijus MANDAL, Jason CROSS
  • IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20190308978
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: April 8, 2019
    Publication date: October 10, 2019
    Inventors: Kang LE, Michael J. SOTH, Gang LIU, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS, Christopher L. CARROLL, Richard T. LEWIS
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20190298729
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 3, 2019
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20190270753
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 5, 2019
    Inventors: Philip JONES, Maria Emilia DI FRANCESCO, Alessia PETROCCHI, Christopher L. CARROLL, Joe MARSZALEK, Barbara CZAKO, Ryan JOHNSON, Jay THEROFF
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 10208059
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: February 19, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20170121342
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: October 4, 2016
    Publication date: May 4, 2017
    Inventors: Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 9481692
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: November 1, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia DiFrancesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20150252058
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: March 12, 2015
    Publication date: September 10, 2015
    Inventors: Philip Jones, Maria Emilia DiFrancesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • Heterocyclic modulators of HIF activity for treatment of disease
    Patent number: 9018380
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: April 28, 2015
    Assignee: Boar of Regents, The University of Texas System
    Inventors: Philip Jones, Maria Emilia DiFrancesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
  • HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
    Publication number: 20140066424
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: March 6, 2014
    Applicant: Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center
    Inventors: Philip Jones, Maria Emilia DiFrancesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff